Report / Tech
Published by NOISE
Personalized mRNA vaccine cuts melanoma recurrence risk by over 40%
From Morning NOISE.
Merck and Moderna reported that their personalized mRNA vaccine reduced the risk of melanoma recurrence or death by 42 percent in a Phase 3 trial. Among 1,137 high-risk patients who had surgery to remove their tumors, those who received the vaccine alongside pembrolizumab had an 82.2 percent recurrence-free rate after about 25 months, versus 70 percent with pembrolizumab alone. The vaccine, tailored to each patient's tumor, is awaiting FDA approval.
Saved versions
These dates record changes to NOISE’s copy. They are not event dates.